pamidronate has been researched along with Sensitivity and Specificity in 18 studies
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tartrate-resistant acid phosphatase isoform-5b (TRACP-5b), a new marker reflecting osteoclast activity, and osteoprotegerin (OPG) were measured in 121 patients with multiple myeloma (MM) at diagnosis, and in 63 of them during pamidronate administration, to define their correlation with the extent of bone disease and disease activity in MM." | 7.72 | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. ( de la Fuente, J; Goldman, JM; Hatjiharissi, E; Meletis, J; Rahemtulla, A; Szydlo, R; Terpos, E; Viniou, N; Yataganas, X, 2003) |
| "A 27-year-old woman with progressive diaphyseal dysplasia (Camurati-Engelmann disease) received pamidronate and corticosteroid therapy for bone pain." | 7.71 | Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease). ( Aburano, T; Inaoka, T; Ishikawa, Y; Makita, Y; Sato, J; Shuke, N; Takahashi, K, 2001) |
| "Multiple myeloma is a disorder of the bone marrow that is associated with bone pain and osteolytic lesions." | 6.69 | Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? ( Dranitsaris, G, 1999) |
| "Twenty-five advanced breast cancer patients who were bisphosphonate naYve and had developed skeletal related complications were identified." | 6.69 | Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. ( Dranitsaris, G; Hsu, T, 1999) |
| "Zoledronic acid also attenuated mechanical hyperalgesia associated with chronic peripheral neuropathy and inflammation in the rat." | 5.31 | Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. ( Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K, 2002) |
| "Tartrate-resistant acid phosphatase isoform-5b (TRACP-5b), a new marker reflecting osteoclast activity, and osteoprotegerin (OPG) were measured in 121 patients with multiple myeloma (MM) at diagnosis, and in 63 of them during pamidronate administration, to define their correlation with the extent of bone disease and disease activity in MM." | 3.72 | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. ( de la Fuente, J; Goldman, JM; Hatjiharissi, E; Meletis, J; Rahemtulla, A; Szydlo, R; Terpos, E; Viniou, N; Yataganas, X, 2003) |
| "A 27-year-old woman with progressive diaphyseal dysplasia (Camurati-Engelmann disease) received pamidronate and corticosteroid therapy for bone pain." | 3.71 | Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease). ( Aburano, T; Inaoka, T; Ishikawa, Y; Makita, Y; Sato, J; Shuke, N; Takahashi, K, 2001) |
| "Multiple myeloma is a disorder of the bone marrow that is associated with bone pain and osteolytic lesions." | 2.69 | Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? ( Dranitsaris, G, 1999) |
| "Twenty-five advanced breast cancer patients who were bisphosphonate naYve and had developed skeletal related complications were identified." | 2.69 | Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. ( Dranitsaris, G; Hsu, T, 1999) |
| "Pamidronate was used as the internal standard." | 1.33 | High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. ( Kwon, KI; Yun, MH, 2006) |
| "Long-term pamidronate treatment of prostate cancer bone metastases does not generally affect the ability to detect bone metastases with Tc99 MDP bone scintigraphy." | 1.32 | Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. ( Higano, CS; King, SH; Ott, SM; Roudier, MP; True, LD; Vessella, RL; Vesselle, H, 2003) |
| "Zoledronic acid also attenuated mechanical hyperalgesia associated with chronic peripheral neuropathy and inflammation in the rat." | 1.31 | Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. ( Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (50.00) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Bhat, CS | 1 |
| Chopra, M | 1 |
| Andronikou, S | 1 |
| Paul, S | 1 |
| Wener-Fligner, Z | 1 |
| Merkoulovitch, A | 1 |
| Holjar-Erlic, I | 1 |
| Menegotto, F | 1 |
| Simpson, E | 1 |
| Grier, D | 1 |
| Ramanan, AV | 1 |
| You, H | 1 |
| Dang, G | 1 |
| Lu, B | 1 |
| Zhang, S | 1 |
| Li, C | 1 |
| Wang, L | 1 |
| Hu, Y | 1 |
| Chen, H | 1 |
| Zhang, J | 1 |
| He, W | 1 |
| Ironside, MS | 1 |
| Reid, DG | 1 |
| Duer, MJ | 1 |
| Walker, K | 1 |
| Medhurst, SJ | 1 |
| Kidd, BL | 1 |
| Glatt, M | 1 |
| Bowes, M | 1 |
| Patel, S | 1 |
| McNair, K | 1 |
| Kesingland, A | 1 |
| Green, J | 1 |
| Chan, O | 1 |
| Fox, AJ | 1 |
| Urban, LA | 1 |
| Roudier, MP | 1 |
| Vesselle, H | 1 |
| True, LD | 1 |
| Higano, CS | 1 |
| Ott, SM | 1 |
| King, SH | 1 |
| Vessella, RL | 1 |
| Wilkinson, JM | 1 |
| Stockley, I | 1 |
| Hamer, AJ | 1 |
| Barrington, NA | 1 |
| Eastell, R | 1 |
| Terpos, E | 1 |
| de la Fuente, J | 1 |
| Szydlo, R | 1 |
| Hatjiharissi, E | 1 |
| Viniou, N | 1 |
| Meletis, J | 1 |
| Yataganas, X | 1 |
| Goldman, JM | 1 |
| Rahemtulla, A | 1 |
| Yun, MH | 1 |
| Kwon, KI | 1 |
| King, LE | 1 |
| Vieth, R | 1 |
| Bonde, M | 1 |
| Garnero, P | 1 |
| Fledelius, C | 1 |
| Qvist, P | 1 |
| Delmas, PD | 1 |
| Christiansen, C | 1 |
| Sparidans, RW | 3 |
| den Hartigh, J | 3 |
| Beijnen, JH | 3 |
| Vermeij, P | 3 |
| Rosano, TG | 1 |
| Peaston, RT | 1 |
| Bone, HG | 1 |
| Woitge, HW | 1 |
| Francis, RM | 1 |
| Seibel, MJ | 1 |
| Broyles, DL | 1 |
| Nielsen, RG | 1 |
| Bussett, EM | 1 |
| Lu, WD | 1 |
| Mizrahi, IA | 1 |
| Nunnelly, PA | 1 |
| Ngo, TA | 1 |
| Noell, J | 1 |
| Christenson, RH | 1 |
| Kress, BC | 1 |
| Dranitsaris, G | 2 |
| Hsu, T | 1 |
| Cremers, S | 1 |
| Inaoka, T | 1 |
| Shuke, N | 1 |
| Sato, J | 1 |
| Ishikawa, Y | 1 |
| Takahashi, K | 1 |
| Aburano, T | 1 |
| Makita, Y | 1 |
4 trials available for pamidronate and Sensitivity and Specificity
| Article | Year |
|---|---|
Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthroplasty, Replacement, Hip; Biomarkers; Bone Resorption; | 2003 |
Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation.
Topics: Adult; Amino Acids; Animals; Antibodies, Monoclonal; Biomarkers; Bone Diseases; Diphosphonates; Fema | 1998 |
Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?
Topics: Antineoplastic Agents; Attitude to Health; Canada; Cost-Benefit Analysis; Diphosphonates; Fractures, | 1999 |
Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Canada; Cancer Care Facilities | 1999 |
14 other studies available for pamidronate and Sensitivity and Specificity
| Article | Year |
|---|---|
Artificial intelligence for interpretation of segments of whole body MRI in CNO: pilot study comparing radiologists versus machine learning algorithm.
Topics: Adolescent; Artificial Intelligence; Bone Density Conservation Agents; Chronic Disease; Disease Prog | 2020 |
Serum Sp17 Autoantibody Serves as a Potential Specific Biomarker in Patients with SAPHO Syndrome.
Topics: Acquired Hyperostosis Syndrome; Adult; Autoantibodies; Biomarkers; Bone and Bones; Bone Density Cons | 2021 |
Correlating sideband patterns with powder patterns for accurate determination of chemical shift parameters in solid-state NMR.
Topics: Diphosphonates; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pamidronate | 2008 |
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.
Topics: Animals; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Hyperalgesia; Hyperes | 2002 |
Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results.
Topics: Antineoplastic Agents; Autopsy; Bone Neoplasms; Diphosphonates; Humans; Infusions, Intravenous; Male | 2003 |
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chem | 2003 |
High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans.
Topics: Alendronate; Bone Density Conservation Agents; Calibration; Chemistry Techniques, Analytical; Chemis | 2006 |
Extraction and measurement of pamidronate from bone samples using automated pre-column derivatization, high-performance liquid chromatography and fluorescence detection.
Topics: Animals; Autoanalysis; Bone and Bones; Calcium; Chemical Precipitation; Chromatography, High Pressur | 1996 |
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen | 1997 |
Determination of pamidronate in urine by ion-pair liquid chromatography after derivatization with 1-naphthylisothiocyanate.
Topics: 1-Naphthylisothiocyanate; Calibration; Chemical Precipitation; Chromatography, High Pressure Liquid; | 1997 |
Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate.
Topics: 1-Naphthylisothiocyanate; Aged; Chemical Precipitation; Chromatography, High Pressure Liquid; Chroma | 1998 |
Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Diseases; Bon | 1998 |
Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate.
Topics: 1-Naphthylisothiocyanate; Automation; Chromatography, Liquid; Diphosphonates; Humans; Indicators and | 1999 |
Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease).
Topics: Administration, Oral; Adult; Camurati-Engelmann Syndrome; Diphosphonates; Drug Therapy, Combination; | 2001 |